logo
logo

Alife Announces Its $22 Million Series A To Modernize And Personalize Fertility Care With Artificial Intelligence

Mar 22, 2022•over 3 years ago

Amount Raised

$22 Million

Round Type

series a

San Francisco

Description

Alife Health, the fertility technology company building artificial intelligence tools to advance in-vitro fertilization (IVF), announced today it has raised $22 million in Series A financing co-led by existing Seed lead Deena Shakir at Lux Capital, and new investors Rebecca Kaden at Union Square Ventures and Anarghya Vardhana at Maveron, both of whom will also be joining Alife's Board of Directors.

Company Information

Company

Alife Health

Location

San Francisco, California, United States

About

Alife's mission is to modernize and personalize the IVF process with cutting edge artificial intelligence technology to improve outcomes and care for all. The company has built a consortium of partnerships with the top clinics and most renowned physicians to bring significant clinical improvements to patients globally. Founded by Paxton Maeder-York in 2020, the company is based in San Francisco and backed by top tier venture capital investors including Lux Capital, Union Square Ventures, and Maveron. To learn more visit www.alifehealth.com.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech